Channel Therapeutics Announces Positive Efficacy Results for the Treatment of Eye Pain Using its NaV1.7 Inhibitor in Multiple Preclinical In Vivo Models
Channel Therapeutics (NYSE: CHRO) has announced positive results from two preclinical animal trials for its eye drop formulation CT2000, targeting both acute and chronic ocular pain. The first trial demonstrated CT2000's effectiveness in treating acute eye pain using a capsaicin model, showing significant pain reduction within 15 minutes. The second trial, using a dry eye disease model, showed cumulative efficacy over a 7-day treatment period.
The company's NaV1.7 inhibitor showed promising results in both trials, supporting its potential broad applications in pain treatment. The global chronic ocular pain market, valued at $7.2 billion in 2023, is projected to reach $12.44 billion by 2032, growing at a CAGR of 6.6%. The acute eye pain market is valued at $404 million. These successful preclinical results pave the way for Channel to initiate Phase 1/II human proof of concept trials.
Channel Therapeutics (NYSE: CHRO) ha annunciato risultati positivi da due studi preclinici su animali per la sua formulazione in collirio CT2000, mirata sia al dolore oculare acuto che cronico. Il primo studio ha dimostrato l'efficacia di CT2000 nel trattamento del dolore oculare acuto utilizzando un modello a base di capsaicina, mostrando una significativa riduzione del dolore entro 15 minuti. Il secondo studio, condotto su un modello di sindrome dell'occhio secco, ha evidenziato un'efficacia cumulativa nel corso di un trattamento di 7 giorni.
L'inibitore NaV1.7 sviluppato dall'azienda ha mostrato risultati promettenti in entrambi gli studi, supportando il suo potenziale impiego esteso nel trattamento del dolore. Il mercato globale del dolore oculare cronico, valutato a 7,2 miliardi di dollari nel 2023, è previsto in crescita fino a 12,44 miliardi di dollari entro il 2032, con un tasso di crescita annuo composto (CAGR) del 6,6%. Il mercato del dolore oculare acuto è valutato a 404 milioni di dollari. Questi risultati preclinici di successo aprono la strada a Channel per avviare studi clinici di Fase 1/II sull'uomo per la prova di concetto.
Channel Therapeutics (NYSE: CHRO) ha anunciado resultados positivos de dos ensayos preclínicos en animales para su formulación en gotas oftálmicas CT2000, dirigida tanto al dolor ocular agudo como crónico. El primer ensayo demostró la eficacia de CT2000 en el tratamiento del dolor ocular agudo usando un modelo de capsaicina, mostrando una reducción significativa del dolor en 15 minutos. El segundo ensayo, utilizando un modelo de enfermedad del ojo seco, mostró eficacia acumulativa durante un período de tratamiento de 7 días.
El inhibidor NaV1.7 de la compañía mostró resultados prometedores en ambos ensayos, apoyando su potencial aplicación amplia en el tratamiento del dolor. El mercado global del dolor ocular crónico, valorado en 7.2 mil millones de dólares en 2023, se proyecta que alcance 12.44 mil millones de dólares para 2032, con una tasa de crecimiento anual compuesta (CAGR) del 6.6%. El mercado del dolor ocular agudo está valorado en 404 millones de dólares. Estos exitosos resultados preclínicos allanan el camino para que Channel inicie ensayos humanos de prueba de concepto en Fase 1/II.
채널 테라퓨틱스 (NYSE: CHRO)는 급성 및 만성 안구 통증을 타겟으로 하는 안약 제형 CT2000에 대한 두 건의 전임상 동물 실험에서 긍정적인 결과를 발표했습니다. 첫 번째 실험에서는 캡사이신 모델을 사용하여 급성 안구 통증 치료에서 CT2000의 효과를 입증했으며, 15분 이내에 통증이 크게 감소하는 것을 확인했습니다. 두 번째 실험에서는 건성안 질환 모델을 사용해 7일간의 치료 기간 동안 누적 효능을 보였습니다.
회사의 NaV1.7 억제제는 두 실험 모두에서 유망한 결과를 보여 통증 치료에 광범위하게 적용될 가능성을 뒷받침합니다. 2023년 기준 72억 달러 규모인 전 세계 만성 안구 통증 시장은 2032년까지 124억 4천만 달러에 이를 것으로 예상되며, 연평균 성장률(CAGR)은 6.6%입니다. 급성 안구 통증 시장은 4억 4백만 달러 규모입니다. 이러한 성공적인 전임상 결과는 채널이 1/II상 인간 개념 증명 시험을 시작할 수 있는 기반을 마련합니다.
Channel Therapeutics (NYSE : CHRO) a annoncé des résultats positifs issus de deux essais précliniques sur animaux pour sa formulation en collyre CT2000, ciblant à la fois la douleur oculaire aiguë et chronique. Le premier essai a démontré l'efficacité de CT2000 dans le traitement de la douleur oculaire aiguë en utilisant un modèle au capsaïcine, avec une réduction significative de la douleur en 15 minutes. Le second essai, utilisant un modèle de sécheresse oculaire, a montré une efficacité cumulative sur une période de traitement de 7 jours.
L'inhibiteur NaV1.7 de la société a donné des résultats prometteurs dans les deux essais, soutenant son potentiel d'applications larges dans le traitement de la douleur. Le marché mondial de la douleur oculaire chronique, évalué à 7,2 milliards de dollars en 2023, devrait atteindre 12,44 milliards de dollars d'ici 2032, avec un taux de croissance annuel composé (CAGR) de 6,6 %. Le marché de la douleur oculaire aiguë est évalué à 404 millions de dollars. Ces résultats précliniques réussis ouvrent la voie à Channel pour lancer des essais humains de preuve de concept en phase 1/II.
Channel Therapeutics (NYSE: CHRO) hat positive Ergebnisse aus zwei präklinischen Tierversuchen für seine Augentropfen-Formulierung CT2000 bekannt gegeben, die sowohl akute als auch chronische Augenschmerzen behandelt. Die erste Studie zeigte die Wirksamkeit von CT2000 bei der Behandlung akuter Augenschmerzen anhand eines Capsaicin-Modells und wies eine signifikante Schmerzlinderung innerhalb von 15 Minuten nach. Die zweite Studie, die ein Modell für das Trockene Auge verwendete, zeigte eine kumulative Wirksamkeit über einen 7-tägigen Behandlungszeitraum.
Der NaV1.7-Inhibitor des Unternehmens zeigte in beiden Studien vielversprechende Ergebnisse und unterstützt damit das Potenzial für breite Anwendungsmöglichkeiten in der Schmerzbehandlung. Der globale Markt für chronische Augenschmerzen, der 2023 mit 7,2 Milliarden US-Dollar bewertet wurde, soll bis 2032 auf 12,44 Milliarden US-Dollar anwachsen, bei einer jährlichen Wachstumsrate (CAGR) von 6,6 %. Der Markt für akute Augenschmerzen wird auf 404 Millionen US-Dollar geschätzt. Diese erfolgreichen präklinischen Ergebnisse ebnen den Weg für Channel, Phase-1/II-Studien am Menschen zur Konzeptbestätigung einzuleiten.
- None.
- Still in preclinical stage, requiring extensive clinical trials before potential commercialization
- Results limited to animal models, human efficacy yet to be demonstrated
Insights
Channel's NaV1.7 inhibitor showed promising preclinical results for eye pain treatment, advancing toward human trials in a multi-billion dollar market.
Channel Therapeutics has demonstrated significant efficacy of its CT2000 formulation in two preclinical animal models for both acute and chronic ocular pain. The results provide compelling evidence for the company's approach of targeting NaV1.7 ion channels for pain management.
In the first trial using a capsaicin model (essentially pepper spray) to simulate acute ocular pain in rabbits, CT2000 reduced pain indicators within 15 minutes of administration, with efficacy lasting at least 60 minutes. The second trial using benzalkonium chloride to induce a dry eye disease model in mice showed pain reduction within a single day of administration, with cumulative efficacy improvements over the 7-day dosing period.
These results build upon Channel's previous positive data from December 2024 for their Depot formulation, creating multiple potential commercial pathways. The company is now positioned to advance to Phase 1/2 human proof-of-concept trials, targeting a substantial market opportunity.
The targeted global chronic ocular pain market is valued at
The preclinical success across multiple pain models suggests the company's NaV1.7 inhibition approach may have broad applicability beyond ocular indications, potentially expanding their addressable market even further if additional trials prove successful.
Global Chronic Ocular Pain Market Valued at US
FREEHOLD, N.J., May 14, 2025 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, (“Channel” or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that it has achieved its predefined endpoints in two pre-clinical animal models of the Company’s eye drop formulations (“CT2000”) for the treatment of both acute ocular pain as well as chronic ocular surface pain commonly associated with dry eye disease.
“We are very pleased with the results of these animal efficacy studies, which adds to the Depot formulation study results announced in December 2024, demonstrating a viable path forward in treating both post-surgical pain and chronic eye pain,” stated Dr. Eric Lang, Chief Medical Officer of Channel. “Additionally, these results support our belief that the inhibition of NaV1.7 has broad applications in treating different pain indications and further supports the genetic validation that NaV1.7 is a potent target for pain,” concluded Dr. Lang.
About the Trials / Results
Trial One
In the first trial, rabbits were treated with capsaicin (i.e., Pepper spray) to mimic an acute ocular insult in a common, validated model for acute eye pain studies. Following the capsaicin treatment, the rabbits were treated with CT2000, which was dosed four times over a 24-hour period. Pain was measured by the number of paw wipes over 60 seconds (paw wipes are a recognized surrogate of eye pain in animal models). The results showed that CT2000 significantly reduced the number of paw wipes within 15 minutes of administration of capsaicin and that CT2000 continued to show efficacy over a 60-minute period following administration. This eye pain model was only validated for a short duration, with the results summarized in the following graph:
Trial Two
In the second trial, benzalkonium chloride (“BAC”) was instilled in mice eyes over a multiday period to create a model of dry eye disease (the study was repeated twice). BAC is a detergent that irritates the eyes and simulates dry eye disease. As with the capsaicin model summarized above, increased paw wipes over 60 seconds were a surrogate to measure ocular pain. Following the induction of dry eye using BAC, the mice were dosed with CT2000 four times per day for 7 days. CT2000 reduced the frequency of paw wipes within a single day of administration and showed cumulative efficacy over time (the analgesic effect appeared to further improve when dosed over several days). The results after one day of dosing CT2000 are summarized in the following graph:
“We are very encouraged with these results, and the opportunity to target a large market that currently does not have many therapeutic options could provide Channel with considerable market opportunities,” stated Frank Knuettel II, Chief Executive Officer of Channel. “Moreover, these results pave the way for Channel to launch Phase 1/II human proof of concept trials,” Mr. Knuettel concluded.
According to Astute Analytica, the global annual chronic eye pain market was valued at
About Channel
Channel Therapeutics Corporation is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The Company’s initial clinical focus is to selectively target the sodium ion-channel known as NaV1.7 for the treatment of various types of systemic chronic pain, acute and chronic eye pain and post-surgical nerve blocks. For company updates and to learn more about Channel, visit www.channeltherapeutics.com or follow us on social media.
Forward-Looking Statements
This press release contains forward-looking statements regarding the Company’s current expectations. These forward-looking statements include, without limitation, references to the Company’s expectations regarding (i) the Company’s belief that the results of its eye pain study, combined with the recently announced results of its Depot formulation demonstrate a viable path forward in treating both post-surgical pain and eye pain, (ii) the Company’s beliefs that the inhibition of NaV1.7 has broad applications in treating different pain indications and that NAV1.7 is a potent target for pain, (iii) the Company’s belief that the Company may be able to target a large market that currently does not have many therapeutic options, which could provide Channel with considerable market opportunities, and (iv) the launch of Phase 1/II human proof of concepts trials and the expected results of those human trials. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ materially from those set forth in such forward-looking statements include, but are not limited to, risks and uncertainties related to there being no guarantee that the trading price of the Company’s Common Stock will be indicative of the Company’s value or that the Company’s Common Stock will become an attractive investment in the future. These and other risks and uncertainties are described more fully in in our filings with the U.S. Securities and Exchange Commission. The information in this press release is provided only as of the date of this press release, and we undertake no obligation to update any forward-looking statements contained in this press release based on new information, future events, or otherwise, except as required by law.
Channel Media and Investor Inquires:
For Investor Inquiries:
Mike Moyer
Managing Director, LifeSci Advisors, LLC
mmoyer@lifesciadvisors.com
Bar charts accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/7301f4d2-dd3b-4822-91cb-6f69833dc865
https://www.globenewswire.com/NewsRoom/AttachmentNg/898c17bd-7683-4e4f-954f-9e0c257ff161
FAQ
What were the key findings of Channel Therapeutics (CHRO) preclinical trials for CT2000?
What is the market potential for Channel Therapeutics' (CHRO) eye pain treatment?
How does Channel Therapeutics' (CHRO) CT2000 eye drop treatment work?
What are the next steps for Channel Therapeutics' (CHRO) eye pain treatment?
How effective was Channel Therapeutics' (CHRO) CT2000 in treating dry eye disease?
